Michael Zinda - Mar 4, 2025 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Role
EVP, CHIEF SCIENTIFIC OFFICER
Signature
/s/ Steve Forte, Attorney-in-Fact
Stock symbol
RPTX
Transactions as of
Mar 4, 2025
Transactions value $
$0
Form type
4
Date filed
3/6/2025, 05:00 PM
Previous filing
Apr 1, 2024
Next filing
Mar 14, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPTX Common Shares Award $0 +14K +19.47% $0.00 85.9K Mar 4, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RPTX Employee Stock Option (right to buy) Award $0 +75K $0.00 75K Mar 4, 2025 Common Shares 75K $1.17 Direct F2
transaction RPTX Employee Stock Option (right to buy) Award $0 +85K $0.00 85K Mar 4, 2025 Common Shares 85K $1.17 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of March 4, 2026, March 4, 2027 and March 4, 2028, subject to Reporting Person continuing to provide service through each such date.
F2 The option will vest in in full on March 4, 2026, subject to Reporting Person continuing to provide service through such date.
F3 Twenty-five percent (25%) of the shares subject to the option shall vest on March 4, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.